Lv1
56 积分 2024-05-25 加入
Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study
2个月前
已完结
EP12.01-63 Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study
2个月前
已关闭
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
3个月前
已完结
Development and immunological evaluation of a Streptococcus suis serotype 2 capsular polysaccharide conjugate vaccine
3个月前
已关闭
Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial
4个月前
已关闭
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
4个月前
已完结
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?
6个月前
已完结
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)
6个月前
已关闭
Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
6个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
7个月前
已完结
皖公网安备34019202002308
